BTIG raises Cullinan Therapeutics price target to $40
BTIG raised its price target on Cullinan Therapeutics to $40.00 per share from $39.00, according to a Benzinga ratings action.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.